Materias dentro de su búsqueda.
Mostrando 161,461 - 161,480 Resultados de 162,377 Para Buscar 'Peñarol~', tiempo de consulta: 2.86s Limitar resultados
  1. 161461
    “…One hundred and fifty-five patients were enrolled with sTBI admitted to the hospital between January 2016 and December 2020 and divided them into a CCS group (n = 75) and a non-CCS group (n = 80) based on the presence of CCS. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Predictive factors for cerebrocardiac syndrome in patients with severe traumatic brain injury: a retrospective cohort study
  2. 161462
    “…The population was divided into 2 cohorts (with and without a history of CVD) and followed until the end of their enrollment coverage, death, or 12 months, whichever came first. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease
  3. 161463
    “…FINDINGS: Between November 27, 2018 and March 11, 2021, a total of 826 participants were screened, and 630 were finally enrolled and randomly assigned (1:1) to either ANV (n = 315) or EFV (n = 315) groups. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96
  4. 161464
    por Seifeldin, Raafat
    Publicado 2003
    “…RESULTS: A total of 690 patients were enrolled in this study; 437 (63.4%) received oxycodone HCl controlled- release and 253 (36.6%) received transdermal fentanyl. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Patient-Reported Utilization Patterns of Fentanyl Transdermal System and Oxycodone Hydrochloride Controlled-Release Among Patients With Chronic Nonmalignant Pain
  5. 161465
    “…Continuously eligible Medicare Part D beneficiaries (Medicare Advantage and prescription drug plans participants only) aged 65 years or older who had an antidiabetic, antihypertensive, or antihyperlipidemic prescription claim between October and December 2010, were identified and followed for the next 2 years. Those enrolled in a home delivery auto refill program were excluded from this analysis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association Between Dispensing Channel and Medication Adherence Among Medicare Beneficiaries Taking Medications to Treat Diabetes, High Blood Pressure, or High Blood Cholesterol
  6. 161466
    “…Members in both groups were required to be continuously enrolled from August 1, 2010, through January 31, 2011. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dalfampridine Prior Authorization Program: A Cohort Study
  7. 161467
    “…The 9 million members are beneficiaries of 10 Blue Cross Blue Shield (BCBS) health plans distributed throughout the United States and the subset of 1.8 million members are enrolled in 1 BCBS health plan in the Northern Plains states. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Utilization, Cost Trends, and Member Cost - Share for Self-Injectable Multiple Sclerosis Drugs-Pharmacy and Medical Benefit Spending From 2004 Through 2007
  8. 161468
    “…The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA 2003) and the subsequent implementation of Medicare Part D in January 2006 for the more than 20 million Medicare beneficiaries enrolled in the Part D benefit formalized MTM services for a subset of high-cost patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Analysis of Pharmacist-Provided Medication Therapy Management(MTM) Services in Community Pharmacies Over 7 Years
  9. 161469
    “…Patients were required to be continuously enrolled for 12 months before and 6 months after ergocalciferol initiation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Treatment of Vitamin D Deficiency Within a Large Integrated Health Care Delivery System
  10. 161470
    “…FINDINGS: Between July 15, 2021, and August 16, 2021, 644 paediatric subjects were screened, of whom 592 were enrolled after verifying that they met the selection criteria: firstly 88 were included in Phase 1 of the study and 504 who completed Phase 2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)
  11. 161471
    “…RESULTS: Of the planned 300 participants, a total of 188 participants (mean [SD] age, 49.1 [12.5] years; 102 [54%] female) were enrolled before the trial was stopped because of the COVID-19 pandemic. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial
  12. 161472
    “…FINDINGS: Between 30 August 2021 and 11 January 2022, a total of 4913 participants were screened and 4036 participants (1956 in Cohort 1 and 2080 in Cohort 2) who met eligibility criteria were enrolled and randomised to receive 2 doses of GBP510/AS03 (n = 3039) or ChAdOx1-S (n = 997). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
  13. 161473
    “…METHODS: In this network meta-analysis, we searched PubMed, MEDLINE, and Web of Science (from database inception to June 24, 2023) for randomised controlled studies, published in English, that enrolled individuals with type 2 diabetes treated with tirzepatide, iGlarLixi, iDegLira, GLP-1RA plus SGLT-2i combination, or high-dose GLP-1RA (dulaglutide 3 mg and 4.5 mg, semaglutide 2 mg) compared with placebo or active comparators. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
  14. 161474
    “…RESULTS: Of 214 patients enrolled (141 men [65.9%]; median age, 67 years [range, 23-85 years]), 139 were randomized to receive cetuximab (n = 67; 45 men [67.2%]; median age, 64 years [range, 34-85 years]) or to be observed (n = 72; 50 men [69.4%]; median age, 68 years [23-85 years]). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
  15. 161475
    “…Here we report the long-term follow-up of a 21- year-old female patient with atypical partial lipodystrophy who developed neutralizing antibodies after treatment with metreleptin and was enrolled in a compassionate use protocol (IND No. 144013) with a leptin receptor agonist (mibavademab) after observing no benefit from setmelanotide (a melanocortin 4 receptor-agonist). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
  16. 161476
    “…A total of 298 women were enrolled in which demographic, anthropometric characteristics, blood pressure (BP), use of hormone therapy (HT), physical activity (PA), smoking status, alcohol intake were obtained. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    THU256 Prevalence And Risk Factors Associated With Diabetes Mellitus Among Middle Aged Women In Southern Brazil: A Population Based Study
  17. 161477
    “…Results: Sixteen patients were enrolled with median body weight (BW) of 51 kg, corresponding to the approximate BW cut point for mibavademab. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
  18. 161478
    “…Results: A total of 211 women were enrolled and the derived early-trimester upper limit of serum TSH (median: 0.92 [0.007-3.08] uIU/mL) was lower than the value provided by the manufacturer (0.27-4.2 uIU/mL), while the upper limit of free T4 (median: 1.28 [0.93-2.15] ng/dL) and free T3 (3.00 [2.30-5.10]ng/dL) were both higher than the non-pregnant value (0.93-1.7 ng/dL and 2.0-4.4 ng/dL, respectively). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI484 Assessment Of Early-trimester Maternal Thyroid Function And Iodine Nutritional Status Of Pregnant Women In Northern Taiwan
  19. 161479
    “…Methods: Patients aged ≥6 to ≤40 years with documented evidence of HO were enrolled in an open-label Phase 2 trial (NCT04725240) and received setmelanotide once daily for 16 weeks. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
  20. 161480
    “…Results: Fifty participants were enrolled (33% recruitment rate); 24 were randomized to the LT4 and 26 to the discontinuation group. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    THU664 Discontinuation Of Low-dose Levothyroxine Therapy For Patients With Subclinical Hypothyroidism Is Feasible: A Pilot, Randomized, Double-blind, Placebo-controlled Trial
Herramientas de búsqueda: RSS